The atypical
antipsychotic medication olanzapine is a useful agent in acute and maintenance treatment of
schizophrenia and related disorders. It has beneficial effects on both positive and negative symptoms, an early onset of
antipsychotic action and a favourable side effect profile. On the other hand,
olanzapine has many reports of causing
weight gain,
glucose metabolism disturbances and
lipidosis. We carried out blood tests (
leptin,
adiponectin, remnant-like
lipoprotein cholesterol (RLP-C), total
cholesterol, HbA1C, 75-OGTT and etc.) on patients with
schizophrenia who had taken
olanzapine. As a result,
leptin, neutral
lipid and RLP-C were significantly correlated by BMI. (The average blood test data and BMI revealed a normal range). Most analysis results of the
lipoprotein fraction by a
polyacrylamide-gel-electrophoresis method were normal patterns. Furthermore, the serum
insulin concentrations from 75 g
glucose tolerance (75 g-OGTT) 30 minutes later, in one third of patients receiving
olanzapine, registered more than 100 microU/ml. The mechanism of the insulin secretion rise by olannzapine is unknown.
Olanzapine may impair
glucose tolerance due in part to increased
insulin resistance. These findings do not necessarily imply that
olanzapine is directly associated with a risk of impairment of
weight gain,
glucose metabolism disturbances and
lipidosis. These results suggest that it is useful to promote diet cure and
exercise therapy with patients with high BMI levels.